Flow cytometric evaluation of cancer stem cell markers in HepG2 cells following sorafenib treatment
Yaprak Dönmez Çakıl1, Mustafa Erinç Sitar2, Zeynep Güneş Özünal3, Damla Kayalı4, Ranan Gülhan Aktas11Department of Histology and Embryology, Maltepe University, Faculty of Medicine, Istanbul, Turkey2Maltepe University Cancer and Stem Cell Research Center, Istanbul, Turkey
3Department of Clinical Biochemistry, Maltepe University, Faculty of Medicine, Istanbul, Turkey
4Maltepe University Experimental Animals Research and Application Center, Istanbul, Turkey
5Department of Medical Pharmacology, Maltepe University, Faculty of Medicine, Istanbul, Turkey
INTRODUCTION: Liver cancer is a leading cause of mortality. Sorafenib resistance and cancer stem cells (CSCs) are among the factors that contribute to a poor prognosis. Different drugs enrich different CSC populations with a variety of CSC markers. This study investigated the expression of CSC markers in HepG2 cells in response to low doses of sorafenib using flow cytometry.
METHODS: The cytotoxicity of sorafenib was determined using a cell counting kit-8 assay. The expressions of the CSC markers CD44, CD90, and CD133 were measured with flow cytometry after treatment with sorafenib for 72 hours.
RESULTS: Sofranib inhibited cell proliferation in a dose-dependent manner. Low-dose sorafenib treatment increased CD44 expression; however, there was a decrease in the expression of CD133. An increasing trend was also seen in CD90 expression, but the difference was not significant.
DISCUSSION AND CONCLUSION: The results indicate that CSC expression varied according to the sorafenib dose administered, which supports the role of CSCs as novel pharmacological targets and highlights the importance of their characterization and the ability to identify them.
Manuscript Language: English